Targeting protein kinases in central nervous system disorders
about
Ten things you should know about protein kinases: IUPHAR Review 14Melanoma brain metastases: an unmet challenge in the era of active therapyThe unstable repeats--three evolving faces of neurological diseaseA Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in CardiomyocytesDevelopment of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionPhenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimizationSelective inhibition of the kinase DYRK1A by targeting its folding processFluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor.Small-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties.Beneficial compaction of spinal cord lesion by migrating astrocytes through glycogen synthase kinase-3 inhibition.CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks.Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases.Molecular targeting of glioblastoma: Drug discovery and therapiesTarget engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.MEK/ERK signaling pathway is required for enterovirus 71 replication in immature dendritic cellsScreening Dyrk1A inhibitors by MALDI-QqQ mass spectrometry: systematic comparison to established radiometric, luminescence, and LC-UV-MS assays.Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discoveryAntiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin.Phenotypic assays to identify agents that induce reactive gliosis: a counter-screen to prioritize compounds for preclinical animal studiesIdentification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy.Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.Mechanisms of regulation of oligodendrocyte development by p38 mitogen-activated protein kinaseBrain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.Disease-Specific Differentiation Between Drugs and Non-Drugs Using Principal Component Analysis of Their Molecular Descriptor Space.Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease ModelsAberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-SecretaseKinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasisNatural products as a source of Alzheimer's drug leads.Death associated protein kinases: molecular structure and brain injury.Oxidation of KCNB1 Potassium Channels Causes Neurotoxicity and Cognitive Impairment in a Mouse Model of Traumatic Brain Injury.
P2860
Q26849417-3353298F-14CE-4E8E-9C09-4E708F798C59Q26995622-1096E5B9-33A3-4084-87A1-B229C2BFD494Q27025923-791FC315-54EB-40A5-80C1-BE463C324B94Q27667526-06F28A46-C3C1-4D2D-BEB4-2319B87593C4Q27679012-3090686D-3142-4EC1-ADCF-B56C9286AF9BQ28476479-50E756C2-B2AA-4871-8943-5379C276ACF2Q28834235-F779131F-246C-4DAB-A018-6720ECAA7A1FQ30393936-B8691470-C9C8-42A8-A008-39A21E70880BQ30417779-5D8BA670-4C7C-4888-A192-92D58E6D68AEQ30516491-2B79AD63-FA42-45F0-9941-F9CE8083E8E0Q30544943-340F866A-3C82-473D-A6E8-6B9D47643F8FQ33654498-EB7652E9-2541-4FC3-A609-F96AC7B0E0A3Q33688478-EF096484-C935-41DE-8FF4-BF59E52F6AC9Q33874259-8758FF80-642A-420B-9F25-C7CEFC1D3086Q33911283-B1AF0EE3-DA59-4FB1-95FB-B3ADB3B28B7CQ34006977-DC03CFCE-3F91-41A8-B690-876D694300C0Q34122676-E4C8C9A9-4205-4AB8-ACCB-F95DF41D640EQ34244752-F1D61C98-9C59-4B12-859C-C1B188E8AE28Q34585992-BFCAB7E6-FCCA-4EB7-A2EB-7C58F0DB1FD5Q35005059-7710EAFD-B5BB-4E00-919D-2D62FACC48A1Q35118036-7B6E6127-9AB0-4973-BF19-4A533BAC6185Q35124699-8FE0E387-EFB9-4C29-AE38-BC04D15BAA90Q35136572-8286FE5C-B752-47BB-8300-D021BD4A1219Q35170361-936B868D-F2F1-4336-AB4A-F0D7854A2F2AQ35518170-798EC53F-63C3-4903-8E23-A7D4D3918D62Q35729506-F17FC069-5BD8-4D2D-9415-08FAC81983DDQ35758331-0A9ED8F0-DD4A-4D0D-B382-19A8CEFCCF44Q35788820-6CFD7F66-A41F-483E-8333-B8498ECF80BAQ35892864-7C3087D9-91C5-4B4B-AECF-E82AA23D4952Q35920872-4B451F5C-5585-4EA1-B8E5-840E8B219C0FQ36040645-B9F5C1E9-A667-4DF3-AD06-9A8DD457A206Q36091270-C1A10B3F-0538-46A3-9C7D-181D11B2F098Q36128825-E04E5627-DA10-4A0B-B60B-71040F7F4CDFQ36450022-20A941D8-D09F-4282-B0B7-0774AFB34212Q36600202-DA6384D8-B28E-4ED8-A138-B8D836FF08F1Q36828224-E923A563-3C5B-4D09-8D23-19D08AA8C54CQ36874745-58FAC038-78B1-4AEF-AA46-84B68F52E701Q37029561-5B345F8F-C788-4EAB-9F06-4DFED86B5035Q37091873-4EB67D4E-9EC0-4DA0-96E4-71161E793978Q37398482-AEB811FA-A0F3-45D0-9477-04B68A9A2C2D
P2860
Targeting protein kinases in central nervous system disorders
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Targeting protein kinases in central nervous system disorders
@ast
Targeting protein kinases in central nervous system disorders
@en
type
label
Targeting protein kinases in central nervous system disorders
@ast
Targeting protein kinases in central nervous system disorders
@en
prefLabel
Targeting protein kinases in central nervous system disorders
@ast
Targeting protein kinases in central nervous system disorders
@en
P2860
P356
P1476
Targeting protein kinases in central nervous system disorders
@en
P2093
Laura K Chico
Linda J Van Eldik
P2860
P2888
P304
P356
10.1038/NRD2999
P577
2009-11-01T00:00:00Z
P5875
P6179
1008024699